Observations on quality of life and disease control in patients with hereditary angioedema

Lanadelumab is administered subcutaneously at 2- to 4-week intervals for long-term prophylaxis in hereditary angioedema (HAE). The effect of longer treatment intervals on disease control or disease-related quality of life (QoL) remains elusive.

To assess whether the reduction of the burden of treatment improves QoL.

The treatment outcome of 56 patients with HAE treated with lanadelumab was assessed. The last documented treatment interval was extracted from patient records; individual disease control and QoL were assessed routinely with the Angioedema Control Test (AECT) and Angioedema Quality of Life Questionnaire (AE-QoL). The evaluation was based on the duration of the injection interval, i.e. equal to or less than 28 days (L ≤ 28) or more than 28 days (L > 28).

In total, 56 patients were included, 23 patients with L ≤ 28 and 33 with L > 28. In the L ≤ 28 group, the mean AECT was 14 points and the AE-QoL was 24 points. In the L > 28 group, the mean AECT was 15.5 points and the AE-QoL was 11.6 points.

We conclude that lanadelumab injection intervals can be generously individualized in many patients with HAE while fully maintaining disease control and QoL.